Cullgen

Targeted protein degradation technology for next-generation therapeutics

San Diego, United States · $121.0M raised

Employees
11–50
Business Model
B2B
Total Funding
$121.0M
Last Round
$35.0M Series CMay 2023
Rounds
5

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Cullgen is a clinical-stage biopharmaceutical company dedicated to developing first-in-class medicines using its proprietary targeted protein degradation (TPD) technology platform. The company develops small molecule targeted protein degraders and degrader antibody conjugates (DACs) that recruit the body's natural protein disposal system to eliminate disease-causing proteins, targeting diseases that lack effective therapeutic approaches. Cullgen raised $40 million in 2023 led by AstraZeneca and CICC Fund, and entered a definitive agreement to be acquired by Gyre Therapeutics in March 2026.

Summary

Cullgen is a Biotech company based in San Diego, United States. It has raised $121.0M in total across 5 rounds, most recently a $35.0M Series C round in May 2023. Investors include 3E Bioventures Capital, Sequoia Capital and HighLight Capital.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CMay 2023
$35.0M

Sign up to see all 5 events

Funding: Seed through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Cullgen on Indexed.vc
<a href="https://indexed.vc/companies/cullgen"><img src="https://indexed.vc/api/badge/company/cullgen" alt="Cullgen on Indexed.vc" width="260" height="76" /></a>